BR112014018670A8 - Compostos de fórmula, composição farmacêutica, uso de um composto, método para o tratamento e invenção - Google Patents

Compostos de fórmula, composição farmacêutica, uso de um composto, método para o tratamento e invenção

Info

Publication number
BR112014018670A8
BR112014018670A8 BR112014018670A BR112014018670A BR112014018670A8 BR 112014018670 A8 BR112014018670 A8 BR 112014018670A8 BR 112014018670 A BR112014018670 A BR 112014018670A BR 112014018670 A BR112014018670 A BR 112014018670A BR 112014018670 A8 BR112014018670 A8 BR 112014018670A8
Authority
BR
Brazil
Prior art keywords
compounds
treatment
pharmaceutical composition
compound
formula compounds
Prior art date
Application number
BR112014018670A
Other languages
English (en)
Other versions
BR112014018670A2 (pt
Inventor
Chen Huifen
Ndubaku Chudi
Wang Lan
R Magnuson Steven
crawford Terry
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014018670A2 publication Critical patent/BR112014018670A2/pt
Publication of BR112014018670A8 publication Critical patent/BR112014018670A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPOSTOS, USOS DOS COMPOSTOS, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA TRATAMENTO OU PROFILAXIA DE CÂNCER E INVENÇÃO. Trata-se de uma invenção que fornece compostos inovadores que têm a fórmula geral (I) em que A, R1 e R2 são conforme descrito no presente documento, sendo que as composições incluem os compostos e uso dos compostos para inibição de angiogênese mediante inibição de MAP4K4.
BR112014018670A 2012-01-30 2013-01-29 Compostos de fórmula, composição farmacêutica, uso de um composto, método para o tratamento e invenção BR112014018670A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261592443P 2012-01-30 2012-01-30
US201261593775P 2012-02-01 2012-02-01
US201261701916P 2012-09-17 2012-09-17
PCT/EP2013/051613 WO2013113669A1 (en) 2012-01-30 2013-01-29 Isoquinoline and naphthyridine derivatives

Publications (2)

Publication Number Publication Date
BR112014018670A2 BR112014018670A2 (pt) 2017-06-20
BR112014018670A8 true BR112014018670A8 (pt) 2017-07-11

Family

ID=47666117

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018670A BR112014018670A8 (pt) 2012-01-30 2013-01-29 Compostos de fórmula, composição farmacêutica, uso de um composto, método para o tratamento e invenção

Country Status (11)

Country Link
US (1) US9586956B2 (pt)
EP (1) EP2809652B1 (pt)
JP (1) JP6363020B2 (pt)
KR (1) KR20140117651A (pt)
CN (1) CN104334532B (pt)
BR (1) BR112014018670A8 (pt)
CA (1) CA2863132A1 (pt)
HK (1) HK1202291A1 (pt)
MX (1) MX353190B (pt)
RU (1) RU2014133390A (pt)
WO (1) WO2013113669A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2951153B1 (en) * 2013-02-01 2019-04-03 Regenacy Pharmaceuticals, LLC Selective hdac3 inhibitors
JP6820854B2 (ja) * 2015-01-18 2021-01-27 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｍａｐ４ｋ４（ｈｇｋ）インヒビター
US11795169B2 (en) 2017-10-13 2023-10-24 Imperial College Innovations Limited MAP4K4 inhibitors
GB201819839D0 (en) * 2018-12-05 2019-01-23 Imperial Innovations Ltd MAP4K4 inhibitors
CN110066259A (zh) * 2019-05-22 2019-07-30 南京合巨药业有限公司 一种n-环戊基-1,1-二氧代-4-硫代吗啉甲酰胺的合成方法
CN110028432A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种（3-氨基-氮杂环丁烷-1-基）-环丙基-甲酮的制备方法
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
WO2022214044A1 (zh) * 2021-04-07 2022-10-13 劲方医药科技(上海)有限公司 氨基取代的吡啶并环类化合物及其制法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
KR20020002433A (ko) * 1999-04-21 2002-01-09 윌리암 에이취 캘넌, 에곤 이 버그 티로신 키나제의 치환된 3-시아노-[1.7],[1.5] 및[1.8]-나프티리딘 억제제
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2009122670A (ru) * 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2010111527A1 (en) * 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use

Also Published As

Publication number Publication date
EP2809652A1 (en) 2014-12-10
CN104334532B (zh) 2018-08-14
CA2863132A1 (en) 2013-08-08
MX353190B (es) 2018-01-05
BR112014018670A2 (pt) 2017-06-20
CN104334532A (zh) 2015-02-04
MX2014009180A (es) 2014-10-13
WO2013113669A1 (en) 2013-08-08
JP2015509921A (ja) 2015-04-02
US20140343036A1 (en) 2014-11-20
EP2809652B1 (en) 2019-05-15
KR20140117651A (ko) 2014-10-07
US9586956B2 (en) 2017-03-07
JP6363020B2 (ja) 2018-07-25
RU2014133390A (ru) 2016-03-20
HK1202291A1 (en) 2015-09-25

Similar Documents

Publication Publication Date Title
BR112014018670A8 (pt) Compostos de fórmula, composição farmacêutica, uso de um composto, método para o tratamento e invenção
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
CL2017002650A1 (es) Compuestos novedosos
BR112016011024A2 (pt) Composto, composição farmacêutica, e, usos dos mesmos
TR201819138T4 (tr) FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri
BR112018003595A2 (pt) análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112018007876A2 (pt) derivado de benzofurano, método de preparação do mesmo e uso do mesmo na medicina
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
UY35300A (es) Formulación de combinación de dos compuestos antivirales
BR112015027527A2 (pt) intensificador de inibidores do homólogo zeste 2
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112012024822B8 (pt) Composto, uso de um composto e composição farmacêutica
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2551 DE 26-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.